Urothelial Cancer

On April 12, 2021, a select group of healthcare professionals involved in the care of patients with urothelial carcinoma (UC) participated in a virtual multidisciplinary panel to discuss best practices in the use of Jelmyto® (mitomycin) for pyelocalyceal solution, which was approved by the US Food and Drug Administration (FDA) in April 2020 for the treatment of adult patients with low-grade upper tract urothelial carcinoma (LG-UTUC). Read More ›

In patients with metastatic urothelial cancer who received previous therapy, as well as in cisplatin-ineligible patients with this cancer, enfortumab vedotin-ejfv (Padcev) improved overall survival (OS), according to new data presented at the 2021 ASCO Genitourinary Cancers Symposium. Read More ›

Preliminary results from a single-arm study demonstrated promising progression-free survival (PFS) and a clinically meaningful objective response rate (ORR) with the combination of pembrolizumab (Keytruda) and nab-paclitaxel (Abraxane) as second- or third-line therapy in patients with advanced urothelial carcinoma. Read More ›

Mitomycin gel (Jelmyto), an alkylating drug, is the first and only FDA-approved treatment for patients with low-grade upper-tract urothelial cancer (UTUC), a rare cancer that affects the lining of the urinary system, and offers a nonsurgical treatment alternative for patients with this rare disease. Although the majority of urothelial cancers occur in the bladder, UTUC is part of a group of urothelial cancers that arise in the lining of the kidney or the ureter. Read More ›